Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Total Current Liabilities (2017 - 2026)

Kiniksa Pharmaceuticals International filings provide 7 years of Total Current Liabilities readings, the most recent being $156.6 million for Q1 2026.

  • On a quarterly basis, Total Current Liabilities rose 61.01% to $156.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $156.6 million, a 61.01% increase, with the full-year FY2025 number at $139.2 million, up 38.33% from a year prior.
  • Total Current Liabilities hit $156.6 million in Q1 2026 for Kiniksa Pharmaceuticals International, up from $139.2 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $156.6 million in Q1 2026 to a low of $36.6 million in Q1 2023.
  • Median Total Current Liabilities over the past 5 years was $64.2 million (2024), compared with a mean of $81.1 million.
  • Biggest five-year swings in Total Current Liabilities: dropped 27.34% in 2023 and later skyrocketed 79.46% in 2024.
  • Kiniksa Pharmaceuticals International's Total Current Liabilities stood at $47.1 million in 2022, then surged by 35.27% to $63.7 million in 2023, then skyrocketed by 58.05% to $100.6 million in 2024, then skyrocketed by 38.33% to $139.2 million in 2025, then increased by 12.52% to $156.6 million in 2026.
  • The last three reported values for Total Current Liabilities were $156.6 million (Q1 2026), $139.2 million (Q4 2025), and $123.6 million (Q3 2025) per Business Quant data.